Status:
COMPLETED
Patient Characteristics in Advanced Renal Cell Carcinoma and Daily Practice Treatment With Nexavar
Lead Sponsor:
Bayer
Conditions:
Carcinoma, Renal Cell
Carcinoma, Renal Cell (Advanced)
Eligibility:
All Genders
18+ years
Brief Summary
Renal cell carcinoma accounts for roughly 3 % of all cancer. It is a rather aggressive cancer type, which means that patients who present with an advanced disease have a rather poor prognosis. When th...
Eligibility Criteria
Inclusion
- Patients with diagnosis of advanced RCC and decision taken by the investigator to prescribe Sorafenib
Exclusion
- Exclusion criteria must be read in conjunction with the local product information
Key Trial Info
Start Date :
July 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2010
Estimated Enrollment :
2840 Patients enrolled
Trial Details
Trial ID
NCT00895674
Start Date
July 1 2006
End Date
August 1 2010
Last Update
September 30 2010
Active Locations (18)
Enter a location and click search to find clinical trials sorted by distance.
1
Many Locations, Argentina
2
Many Locations, Austria
3
Many Locations, China
4
Many Locations, Colombia